Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia

Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia

Abstract Background Outcomes for patients with relapsed acute lymphoblastic leukemia (ALL) are poor and there is a need for novel therapies to improve outcomes. Targeted inhibition of WEE1 with small-molecule inhibitor adavosertib (AZD1775) has emerged as a therapeutic strategy to sensitize cancer c...

Full description

Bibliographic Details
Main Authors: Hayden L. Bell, Helen J. Blair, Mankaran Singh, Anthony V. Moorman, Olaf Heidenreich, Frederik W. van Delft, John Lunec, Julie A. E. Irving
Format: Article
Language:English
Published: BMC 2023-09-01
Series:Cancer Cell International
Subjects:
WEE1
Inhibitors
Leukemia
High-risk
Relapse
Translational
Online Access:https://doi.org/10.1186/s12935-023-03057-8

Internet

https://doi.org/10.1186/s12935-023-03057-8

Similar Items